Welcome to our dedicated page for Larimar Therapeutics SEC filings (Ticker: LRMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Larimar Therapeutics, Inc. (NASDAQ: LRMR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Larimar is a clinical-stage biotechnology company focused on complex rare diseases, with its lead compound, nomlabofusp, in development as a potential treatment for Friedreich’s ataxia. Its SEC filings offer detailed information on clinical progress, financial condition, capital structure, and key corporate events.
Investors can review Larimar’s current reports on Form 8-K, which the company uses to announce material developments. Recent 8-K filings have covered topics such as positive data from the long-term open-label study of nomlabofusp, FDA safety database recommendations and regulatory timelines for a planned Biologics License Application seeking accelerated approval, quarterly financial results, and updates to investor slide presentations. Other 8-Ks describe capital markets transactions, including an underwritten public offering of common stock and an exchange agreement that created Series A convertible preferred stock with defined conversion and ranking terms.
In addition to 8-Ks, users can access Larimar’s periodic reports (Forms 10-K and 10-Q, when available) for broader discussions of research and development expenses, cash position, and risk factors related to the nomlabofusp program and the company’s rare disease focus. These filings elaborate on how Larimar funds its clinical activities, including proceeds from equity offerings and the intended use of capital for research, development, and pre-commercialization efforts.
Stock Titan enhances these documents with AI-powered summaries that highlight the main points of lengthy filings, helping readers quickly identify disclosures related to nomlabofusp’s clinical data, FDA interactions, safety database requirements, and financing arrangements. Real-time updates from EDGAR ensure that new Larimar filings, such as additional 8-Ks, 10-Qs, or 10-Ks, appear promptly, while Form 4 insider transaction reports can be monitored to see how company insiders are transacting in LRMR shares.
Blue Owl Capital Holdings LP filed an amended Schedule 13G reporting beneficial ownership of 8,464,663 Larimar Therapeutics common shares, representing 9.99 % of the class. This total includes 6,823,690 common shares and 1,640,973 shares issuable upon conversion of 250,000 Series A convertible preferred shares, which are subject to a 9.9% conversion blocker.
Blue Owl reports sole voting and dispositive power over all of these securities and states they were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Larimar Therapeutics.
Larimar Therapeutics reported an insider equity award for Chief Development Officer Shankar Gopi. On January 26, 2026, he received 153,822 stock options with a $3.60 exercise price and vesting over four years, starting 25% on January 26, 2027, then monthly thereafter.
He also acquired 25,637 shares of common stock for $0.00 per share, represented by restricted stock units, bringing his directly held common stock to 76,443 shares. All transactions were classified as awards and reported as directly owned.
Larimar Therapeutics Chief Medical Officer Clayton Russell received new equity awards. On January 26, 2026, he was granted 25,637 restricted stock units, representing the right to receive an equal number of Larimar common shares at settlement, bringing his directly held common stock to 71,443 shares.
He was also granted stock options for 153,822 shares at an exercise price of $3.60. These options vest 25% on January 26, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months, contingent on continued service.
Larimar Therapeutics President and CEO Carole Ben-Maimon reported equity awards dated January 26, 2026. She received 100,100 shares of Common Stock for no cash cost, structured as restricted stock units that each convert into one share upon settlement.
She was also granted a stock option for 600,600 shares of Common Stock at an exercise price of $3.60 per share. The option vests 25% on January 26, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months, subject to her continued service. After these grants, she directly holds 368,276 shares of Common Stock and 600,600 stock options, while several irrevocable family trusts for which she serves as trustee each hold 31,155 or 31,156 shares; she disclaims beneficial ownership of those trust shares except to any pecuniary interest.
Larimar Therapeutics reported an equity compensation grant to its Chief Financial Officer, Michael Celano. On January 26, 2026, he received 37,604 shares of Common Stock at a price of
Larimar Therapeutics, Inc. entered into an exchange agreement with Blue Owl Healthcare Opportunities IV Public Investments LP, where the investor will exchange 2,500,000 shares of Larimar common stock for 250,000 shares of Series A convertible preferred stock. Each preferred share is convertible into 10 common shares, but the preferred stock generally carries no voting rights and shares in liquidation proceeds on the same basis as common stock, subject to its ranking terms. In connection with this exchange, Larimar amended the existing designation to increase authorized Series A preferred shares from 250,000 to 500,000. The exchange is expected to close on January 23, 2026, and the preferred shares will be issued without registration under the Securities Act in reliance on Section 3(a)(9).
Larimar Therapeutics, Inc. reported that it had approximately $136.9 million in cash, cash equivalents and marketable securities as of December 31, 2025. This figure was shared in an updated slide presentation posted on the company’s website and is described as unaudited, preliminary and prepared by management, meaning it could change once the company completes its quarter- and year-end financial closing processes.
The company notes that its independent auditor, PricewaterhouseCoopers LLP, has not audited, reviewed, compiled or performed procedures on this preliminary cash figure and provides no assurance on it. Larimar also posted an updated corporate presentation, attached as Exhibit 99.1, which its representatives may use in meetings with investors, analysts and other parties.
Larimar Therapeutics entered an exchange agreement with Blue Owl Healthcare Opportunities IV Public Investments LP, under which the stockholder exchanged 2,500,000 shares of common stock for 250,000 shares of newly designated Series A convertible preferred stock.
Each preferred share is convertible into 10 common shares, subject to a 9.99% beneficial ownership Conversion Blocker, which holders may increase to 19.99% upon 60 days’ notice. The Preferred Stock generally has no voting rights other than as required by law and to approve changes to its terms, participates pari passu with common stock in dividends and liquidation on an as-converted basis, and was issued in reliance on the Section 3(a)(9) exemption from Securities Act registration.
Larimar Therapeutics (LRMR) filed an 8-K announcing an updated corporate presentation posted to its website and furnished as Exhibit 99.1, dated November 10, 2025. The company plans to use the slide deck in meetings with investors, analysts, and other stakeholders.
This is an informational update intended to support outreach and communication. The filing also lists the company’s common stock on the Nasdaq Global Market under the symbol LRMR.
Larimar Therapeutics (LRMR) reported Q3 2025 results highlighted by increased R&D investment as it advances nomlabofusp for Friedreich’s ataxia. The company posted a net loss of $47.7 million, driven by research and development expense of $44.9 million and general and administrative expense of $4.6 million. Cash, cash equivalents and marketable securities totaled $175.4 million as of September 30, 2025, supported by $65.0 million of net proceeds from a July 31 underwritten offering.
Management reiterated its regulatory path: participation in FDA’s START pilot, FDA feedback that skin frataxin (FXN) concentration may be considered a reasonably likely surrogate endpoint subject to future review, and BLA safety database parameters. The company targets a BLA submission for accelerated approval in Q2 2026 and plans a regulatory and study status update in Q1 2026. In its open-label study, 65 participants have received at least one dose, with directional improvements across clinical outcomes and FXN levels; 7 anaphylaxis events occurred early in dosing and the firm is implementing a modified starting regimen agreed with FDA. Shares outstanding were 85,590,392 as of November 3, 2025.
FAQ
What is the current stock price of Larimar Therapeutics (LRMR)?
What is the market cap of Larimar Therapeutics (LRMR)?
